[PDF][PDF] Hepatic stellate cells and liver fibrosis

JE Puche, Y Saiman, SL Friedman - Compr Physiol, 2013 - academia.edu
Hepatic stellate cells are resident perisinusoidal cells distributed throughout the liver, with a
remarkable range of functions in normal and injured liver. Derived embryologically from …

Fibrosis regression after eradication of hepatitis C virus: from bench to bedside

DC Rockey, SL Friedman - Gastroenterology, 2021 - Elsevier
Hepatitis C virus (HCV) infection and its complications have been the major cause of
cirrhosis and its complications for several decades in the Western world. Until recently …

[HTML][HTML] The therapeutic potential of galectin-3 inhibition in fibrotic disease

RJ Slack, R Mills, AC Mackinnon - … Journal of Biochemistry & Cell Biology, 2021 - Elsevier
Galectin-3 is a beta-galactoside-binding mammalian lectin and part of the 15 member
galectin family that are evolutionarily highly conserved. It is the only chimeric protein with a …

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

X Cai, J Wang, J Wang, Q Zhou, B Yang, Q He… - Pharmacological …, 2020 - Elsevier
Liver fibrosis is a dynamic wound-healing process characterized by the net accumulation of
extracellular matrix. There is no efficient antifibrotic therapy other than liver transplantation to …

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

PG Traber, H Chou, E Zomer, F Hong, A Klyosov… - PloS one, 2013 - journals.plos.org
Galectin-3 protein is critical to the development of liver fibrosis because galectin-3 null mice
have attenuated fibrosis after liver injury. Therefore, we examined the ability of novel …

Galectin-3 in autoimmunity and autoimmune diseases

FL de Oliveira, M Gatto, N Bassi… - Experimental …, 2015 - journals.sagepub.com
Galectin-3 (gal-3) is a β-galactoside-binding lectin, which regulates cell–cell and
extracellular interactions during self/non-self-antigen recognition and cellular activation …

Therapy of experimental NASH and fibrosis with galectin inhibitors

PG Traber, E Zomer - PloS one, 2013 - journals.plos.org
Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem
without effective therapy. Some data suggest that galectin-3 null mice are resistant to the …

The race to bash NASH: emerging targets and drug development in a complex liver disease

FA Romero, CT Jones, Y Xu, M Fenaux… - Journal of medicinal …, 2020 - ACS Publications
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease
(NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH …

Development of galectin-3 targeting drugs for therapeutic applications in various diseases

R Ahmed, K Anam, H Ahmed - International Journal of Molecular …, 2023 - mdpi.com
Galectin-3 (Gal3) is one of the most studied members of the galectin family that mediate
various biological processes such as growth regulation, immune function, cancer …

Tissue-and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and disease

J Nio-Kobayashi - Anatomical science international, 2017 - Springer
Fifteen galectins, β-galactose-binding animal lectins, are known to be distributed throughout
the body. We herein summarize current knowledge on the tissue-and cell-specific …